Frankfurt
13.02.26 | 08:00
4,080 Euro
-0,97 % -0,040
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.02. | LifeVantage outlines $185M-$200M revenue target and new $60M buyback amid GLP-1 headwinds and LoveBiome integration | 1 | Seeking Alpha | ||
| 04.02. | LifeVantage Q2 2026: Gewinnziel erreicht, Umsatzprognose verfehlt | 2 | Investing.com Deutsch | ||
| 04.02. | LifeVantage CEO Steve Fife to retire in April after nine-year tenure | 3 | Investing.com | ||
| 04.02. | LifeVantage announces $0.045 quarterly dividend payable in March | 1 | Investing.com | ||
| 04.02. | LifeVantage CEO Steve Fife to retire in April | 1 | Seeking Alpha | ||
| 04.02. | LifeVantage Corporation: LifeVantage Declares Quarterly Dividend | 1 | GlobeNewswire (USA) | ||
| 04.02. | LifeVantage Corporation: LifeVantage Announces Planned Retirement of Steve Fife and CEO Succession Plan | 351 | GlobeNewswire (Europe) | SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health at the cellular level... ► Artikel lesen | |
| 04.02. | LifeVantage Non-GAAP EPS of $0.15 in-line, revenue of $48.9M misses by $5.5M | 2 | Seeking Alpha | ||
| LIFEVANTAGE Aktie jetzt für 0€ handeln | |||||
| 04.02. | LifeVantage Corporation: LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2026 | 1.727 | GlobeNewswire (Europe) | SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular... ► Artikel lesen | |
| 04.02. | Lifevantage Corp - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 04.02. | Lifevantage Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 21.01. | LifeVantage Corporation: LifeVantage to Announce Second Quarter Fiscal Year 2026 Results on February 4, 2026 | 1 | GlobeNewswire (USA) | ||
| 12.01. | LifeVantage Corporation: LifeVantage Kicked Off 2026 With Global Kickoff, a Virtual Event Showcasing Innovation and Integration | 1 | GlobeNewswire (USA) | ||
| 07.01. | LifeVantage appoints Mike Edwards as chief technology officer | 1 | Investing.com | ||
| 07.01. | LifeVantage Corporation: LifeVantage Appoints Seasoned Technology Executive Mike Edwards as Chief Technology Officer to Drive Digital Innovation | 191 | GlobeNewswire (Europe) | SALT LAKE CITY, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular... ► Artikel lesen | |
| 10.12.25 | LifeVantage Corporation: LifeVantage to Participate in Water Tower Fireside Chat on Thursday, December 11, 2025 | 1 | GlobeNewswire (USA) | ||
| 09.12.25 | Lifevantage Corp - 8-K, Current Report | - | SEC Filings | ||
| 01.12.25 | Dividendenbekanntmachungen (01.12.2025) | 12.012 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACNB CORPORATION US0008681092 0,38 USD 0,3276 EUR ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,18 USD 0,1551 EUR AGNICO EAGLE MINES... ► Artikel lesen | |
| 12.11.25 | Lifevantage Corp - 8-K, Current Report | - | SEC Filings | ||
| 05.11.25 | LifeVantage outlines $225M-$240M fiscal 2026 revenue target as LoveBiome integration advances | 2 | Seeking Alpha |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 130,42 | -0,08 % | Gilead Sciences: Weitere Zukäufe geplant - diese Aktie könnte profitieren | Seit September hatten wir immer wieder auf ein bevorstehendes Ausbruchsszenario bei der Aktie des Pharmariesens Gilead Sciences verwiesen - und schlussendlich eindrucksvoll Recht behalten. Seit unseres... ► Artikel lesen | |
| ABBVIE | 195,00 | 0,00 % | AbbVie files lawsuit over selection of Botox for Medicare price negotiations | ||
| ELI LILLY | 879,50 | +0,40 % | Trader-Interview mit Andreas Bernstein & Thomas May: Telekom, Fraport, Microsoft, Eli Lilly, Cadence | In dieser Ausgabe des Trader-Interviews sprechen Thomay May und Andreas Bernstein über die aktuelle Marktsituation und .. ► Artikel lesen | |
| MERCK & CO | 102,40 | 0,00 % | FDA Approves Merck's Keytruda And Keytruda Qlx For Platinum-Resistant Ovarian Cancer | KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) on Wednesday said the U.S. Food and Drug Administration has approved Keytruda and Keytruda Qlx, a subcutaneous formulation of Keytruda, in combination... ► Artikel lesen | |
| TEVA | 28,600 | -0,35 % | Teva Pharmaceuticals - TEVA: Abschied vom Generika-Geschäft! Was nun? | Strategische Neuausrichtung! Pullback-Setup bei der Teva-Aktie! Kommt der Bounce nach 7 roten Kerzen? Quartalszahlen erst im Mai! Teva Pharmaceuticals (TEVA) - ISIN US8816242098 Rückblick: Mit +88 Prozent... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 416,50 | +0,59 % | Vertex Pharmaceuticals Inc. Reports Rise In Q4 Bottom Line | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported earnings for its fourth quarter that Increases, from last yearThe company's earnings came in at $1.191 billion... ► Artikel lesen | |
| INCYTE | 85,18 | +0,02 % | Incyte Corporation Q4 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Incyte Corporation (INCY) announced earnings for its fourth quarter that Increased from last year and beat the Street estimates.The company's bottom line totaled $299.3... ► Artikel lesen | |
| EYEPOINT | 10,725 | 0,00 % | RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline | ||
| ORGANIGRAM GLOBAL | 1,100 | +1,85 % | Organigram. Buy, Sell or Hold? | ||
| IONIS PHARMACEUTICALS | 68,62 | +1,06 % | Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts | ||
| QUANTUM BIOPHARMA | 3,160 | +1,94 % | Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) | TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 61,00 | +0,83 % | Nektar Therapeutics: New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing | 71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively
Meaningful... ► Artikel lesen | |
| AMARIN | 12,400 | 0,00 % | Amarin Corporation plc: Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA/VAZKEPA (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization | DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on... ► Artikel lesen | |
| MEDPACE | 361,40 | +0,22 % | Zelluna ASA: Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial | Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy productPartnership follows submission of the Clinical Trial Application (CTA) to the MHRA... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 154,00 | 0,00 % | Ligand Pharmaceuticals: Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 |
LIFEVANTAGE CORPORATION gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 4,080 Euro und damit -0,97 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIFEVANTAGE CORPORATION finden Sie auf Wallstreet Online.